Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer

Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer is organized by Society for Translational Oncology (STO).

Released: 12/10/2020
Expires: 12/10/2022

CME Accreditation:
The Society for Translational Oncology designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Learning Objectives:
• Describe the association between genetic alterations of DNA damage response genes in tumor tissues and clinical outcomes in advanced urothelial cancer.
• Describe the association between alteration of the ATM gene and overall survival.